Business Context and Reporting Period
Company: Eterna Therapeutics Inc. (Ticker: ERNA)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Eterna is a preclinical-stage synthetic allogeneic iMSC therapy company focused on developing off-the-shelf cellular therapies for solid tumors (specifically platinum-resistant ovarian cancer via ERNA-101) and autoimmune diseases (via ERNA-102). The company relies heavily on in-licensed intellectual property from Factor Bioscience Limited under a new Exclusive License and Collaboration Agreement (Factor L&C Agreement) entered into in September 2024.
Key Financial Metrics
| Metric (in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $582 | $68 |
| Net Loss | $(44,539) | $(21,668) |
| Operating Loss | $(15,674) | $(21,135) |
| Cash and Cash Equivalents (Year-End) | $1,729 | $7,575 |
| Accumulated Deficit | $(231,536) | $(186,981) |
| Stockholders' Equity | $1,701 | $2,233 |
Debt and Liquidity: As of December 31, 2024, the company had no outstanding convertible notes or bridge notes following a series of exchange transactions in October 2024. The company holds approximately $1.7 million in cash. Management has disclosed substantial doubt regarding the company's ability to continue as a going concern for the 12 months following the issuance of the financial statements without additional capital.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased to $0.6 million from $0.1 million, primarily due to the acceleration of deferred revenue recognition ($0.5 million) related to the Lineage Cell Therapeutics agreement following its assignment to Factor Bioscience.
- Net Loss Expansion: Net loss more than doubled to $44.5 million. This was driven by a $22.4 million non-cash loss on extinguishment of debt resulting from the exchange of convertible notes and warrants for common stock in October 2024, and increased interest expense related to bridge notes.
- Operating Expense Reduction: Total operating expenses decreased by $4.8 million to $16.2 million. This reduction was largely due to a $1.6 million gain on lease termination (related to a Somerville, MA facility) and reduced professional fees and payroll costs.
- Capital Structure Changes: In September and October 2024, the company executed significant transactions including the issuance of bridge notes, a private placement of common stock, and the exchange of outstanding warrants and convertible notes for approximately 45.9 million shares of common stock.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The company explicitly states it does not have sufficient capital to fund operations for the next 12 months. It requires substantial additional financing to continue as a going concern. Failure to raise capital could lead to bankruptcy or liquidation.
- Nasdaq Delisting Risks: The company received notices from Nasdaq in late 2024 regarding non-compliance with the Bid Price Rule (stock price below $1.00) and the Market Value of Listed Securities (MVLS) Rule (market value below $35 million). Compliance periods extend into mid-2025.
- Intellectual Property Dependency: The business is substantially dependent on the Factor L&C Agreement. Termination of this license would significantly harm product development. The company pays Factor Bioscience approximately $0.2 million per month for the first year of the agreement.
- Unusual Items:
- Loss on Extinguishment of Debt: A $22.4 million charge recognized in 2024 due to the modification and exchange of debt instruments.
- Gain on Lease Termination: A $1.6 million gain recognized from terminating a sublease, saving approximately $72 million in future rental obligations.
- Outlook: The company expects to complete IND-enabling studies for its lead candidate, ERNA-101, by 2026. It is actively seeking strategic partnerships to co-develop assets.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.7 million cash balance against current burn rates and the timeline for the next capital raise.
- Financing Status: Confirm the status of the Standby Equity Purchase Agreement (SEPA) with Lincoln Park Capital Fund (approx. $9.7 million remaining capacity) and any new debt or equity issuances post-filing.
- Nasdaq Compliance: Monitor the stock price and market capitalization to assess the risk of delisting before the June/July 2025 compliance deadlines.
- Factor Bioscience Relationship: Review the terms of the Factor L&C Agreement and the company's ability to meet the monthly payment obligations ($0.2 million) and milestone requirements.
- Trademark Settlement: Verify the timeline for phasing out the "ETERNA" trademark (deadline extended to March 31, 2025) to avoid daily penalties.